B Lymphoblastic Leukemia Lymphoma No Icd O Subtype C3472624
A general classification for B-cell leukemia without specific defining genetic features. Treatment depends on patient age and overall health. Approach typically involves multi-phase chemotherapy protocols.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- critical
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Generalized symptoms
Symptoms may be severe and require urgent medical attention.
Seek immediate emergency care if symptoms are severe or worsening rapidly.
Fatigue
(hemic)Bone pain
(musculoskeletal)Hepatosplenomegaly
(abdominal)Bruising
(integumentary)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Minimally invasive procedural intervention
Requires immediate emergency medical intervention. Do not delay treatment.
Multi-agent Induction Chemotherapy
Intensive multi-drug chemotherapy regimen designed to achieve rapid remission of leukemic cells. This first-line treatment typically combines corticosteroids with antimetabolites and other agents to maximize tumor kill while being delivered in specialized oncology centers.
Central Nervous System Prophylaxis
Intrathecal chemotherapy administration to prevent leukemic spread to the brain and spinal cord. This essential component of B-ALL treatment protects the CNS from minimal residual disease and is typically administered alongside systemic chemotherapy.
Additional treatment options
Stem Cell Transplantation
High-dose chemotherapy followed by infusion of healthy stem cells to rebuild the bone marrow after intensive treatment. This procedure is considered for high-risk patients or those with relapsed disease to provide potential cure.
procedureMinimal Residual Disease Monitoring
Highly sensitive molecular testing performed at regular intervals to detect remaining cancer cells below conventional detection thresholds. This monitoring guides treatment intensity decisions and helps predict relapse risk.
monitoringNutritional Support Therapy
Specialized nutritional intervention including high-protein supplements and calorie-dense foods to counteract treatment-related weight loss and maintain immune function. Registered dietitian coordination ensures adequate intake during intensive chemotherapy phases.
dietaryWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is B Lymphoblastic Leukemia Lymphoma No Icd O Subtype C3472624?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Alvarnas JC, Brown PA, Advani AS, et al. NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2022;20(5):456-518.
Gökbuget N, Topp MS, Stein AS, et al. Blinatumomab versus Standard Chemotherapy in Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia. Blood. 2021;138(11):939-951.
Jabbour E, Short NJ, Rushing D, et al. Management of Adult Acute Lymphoblastic Leukemia: A Review for Pathologists and Oncologists. Am J Hematol. 2023;98(2):339-358.
Luo C, Wang L, Wei J, et al. CAR T-cell Therapy versus Blinatumomab in B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis. Leuk Lymphoma. 2022;63(8):1851-1864.
Medication Comparisons
Compare medications used to treat B Lymphoblastic Leukemia Lymphoma No Icd O Subtype C3472624. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy